Table 1.
Characteristics of Patients According to TTField Use
| TTFields (n = 210) (%) | No TTFields (n = 327) (%) | ||
|---|---|---|---|
| Age | (years old) (mean + SD) | 54.0 ± 12.3 | 60.0 ± 13.8 |
| Sex | Male | 132 (63) | 185 (57) |
| Female | 78 (37) | 142 (43) | |
| Social status before disease onset | Employed | 152 (73) | 188 (58) |
| Unemployed | 57 (27) | 137 (42) | |
| Caregiver | Spouse | 172 (82) | 221 (68) |
| Others | 36 (17) | 85 (26) | |
| Solitude | 2 (1) | 21 (6) | |
| Tumor location | Frontal | 81 (39) | 110 (34) |
| Temporal | 59 (28) | 103 (32) | |
| Parietal | 50 (24) | 80 (25) | |
| Occipital | 5 (2) | 12 (4) | |
| Insula | 3 (1) | 10 (3) | |
| Basal ganglia | 4 (2) | 4 (1) | |
| Thalamus | 7 (3) | 6 (2) | |
| Extent of resection | No residual enhancing lesion | 126 (60) | 219 (67) |
| Unmeasurable residual enhancement | 39 (19) | 42 (13) | |
| Measurable residual enhancement | 31 (15) | 42 (13) | |
| Biopsy | 14 (7) | 24 (7) | |
| Implantation of carmustine wafers | Yes | 64 (30) | 97 (30) |
| No | 146 (70) | 229 (70) | |
| Photodynamic therapy | Yes | 18 (9) | 23 (7) |
| No | 192 (91) | 304 (93) | |
| Residual lesion before adjuvant TMZa | No enhancing lesion | 132 (63) | 215 (66) |
| Residual enhancement | 78 (37) | 111 (34) | |
| KPS before adjuvant TMZ | 100 | 36 (17) | 40 (12) |
| 90 | 92 (44) | 132 (40) | |
| 80 | 40 (19) | 73 (22) | |
| 70 | 42 (20) | 82 (25) | |
| Japan Coma Scale before adjuvant TMZ | 0 | 181 (86) | 259 (80) |
| 1–3 | 29 (14) | 66 (20) | |
| Paresis before adjuvant TMZ | Absent | 175 (84) | 280 (86) |
| Present | 34 (16) | 46 (14) | |
| Apasia before adjuvant TMZ | Absent | 190 (90) | 280 (86) |
| Present | 20 (10) | 45 (14) | |
| Cycles of adjuvant TMZ | (Median cycles) | 0–53 (12) | 0–43 (12) |
| MGMTpromoter methylation status | Methylated | 44 (21) | 69 (21) |
| Unmethylated | 62 (30) | 66 (20) | |
| No data | 104 (49) | 192 (59) | |
| Mutation status in the IDH gene | Wild-type | 192 (92) | 301 (95) |
| Mutant | 16 (8) | 17(5) |
Abbreviations: IDH, isocitrate dehydrogenase; KPS, Karnofsky Performance Status; MGMT, O6-methylguanine DNA methyltransferase; TMZ, temozolomide; TTFields, tumor-treating fields.
aOne case was not examined due to asthma.